Roles Of The Gh-Igf-Igfbp Axis In Hepatic Fibrosis
Downloads
Hepatic fibrosis refers to the excessive deposition of collagen fibers and subsequently evolves liver cirrhosis to HCC. Currently, there is not successful therapeutic approach to liver fibrosis in addition to liver transplantation for patients with decompensate liver cirrhosis. Therefore, it is important to identify cellular and molecular mechanism that promote liver damage or provide hepatoprotection for development of therapeutic approaches. The GH-IGF-IGFBP axis consists of growth hormone (GH), two growth factors (IGF-I and IGF-II), theirreceptors (IGF-IR and IGF-IIR) and a group of binding proteins (IGFBP1-7). In the recent years, accumulating evidences have demonstrated that the elements of this axis play the important roles in the pathogenesis of liver fibrosis. In this review, we first summarize genomic and pathological information of the IGF-IGFBP axis and further review the roles of each element of this axis in the pathogenesis of liver fibrosis.
Duval F, Moreno-Cuevas JE, González-Garza
MT, Maldonado-Bernal C, Cruz-VegaDE. Liver
fibrosis and mechanisms of the protective action
of medicinal plants targeting inflammation and
the immune response.Int J Inflam. 2015;
:943497.
Liu JP, Baker J, Perkins AS, Robertson EJ,
Efstratiadis A. Mice carrying null mutations of
the genes encoding insulin-like growth factor I
(Igf-1) and type 1 IGF receptor (Igf1r). Cell.
Oct 8; 75(1):59-72.
Yu H, Rohan T. Role of the insulin-like growth
factor family in cancer development and
progression. J Natl Cancer Inst. 2000 Sep
;92(18):1472-89.
Mónica Enguita-Germán, Puri Fortes. Targeting
the insulin-like growth factor pathway in
hepatocellular carcinoma. World J Hepatol 2014;
(10): 716-737.
Toshikuni N, Tsutsumi M, Arisawa T. Clinical
differences between alcoholic
liver disease and nonalcoholic fatty liver disease.
World J Gastroenterol. 2014
Jul 14;20(26):8393-406.
Karen Bonefeld, Søren
Møller.Insulin-likegrowthfactor-Iandtheliver,Liv
er International 2011;911-919.
Dai B, Ruan B, Wu J, Wang J, Shang R, Sun W,
Li X, Dou K, Wang D, Li Y.Insulin-like growth
factor binding protein-1 inhibits cancer cell
invasion and isassociated with poor prognosis in
hepatocellular carcinoma. Int J ClinExpPathol.
Aug 15;7(9):5645-54.
Aleem E, Elshayeb A, Elhabachi N, Mansour
AR, Gowily A, Hela A. Serum IGFBP-3 is a
more effective predictor than IGF-1 and IGF-2
for the development ofhepatocellular carcinoma
in patients with chronic HCV infection. Oncol
Lett. 2012 Mar;3(3):704-712.
El-Serag HB, Lau M, Eschbach K, Davila J,
Goodwin J. Epidemiology of hepatocellular
carcinoma in Hispanics in the United States.
Arch Intern Med. 2007 Oct 8; 167(18):1983-9.
Chan AC, Poon RT, Chok KS, Cheung TT,
Chan SC, Lo CM. Feasibility of laparoscopic
re-resection for patients with recurrent
hepatocellular carcinoma.World J Surg. 2014
May; 38(5):1141-6.
Lee YA, Wallace MC, Friedman
SL.pathobiology of liver fibrosis: translation
success story. Gut 2015; 64(5):830-841.
O.A Gressner, M.S. Rizk, E. Kovalenko, R.
weiskirchen and A.M. Gressner.Changing the
pathogenetic roadmap of liver fibrosis? Where
did it start; where will it go? J Gastroenterol
Hepatol2008, 23:1024-1035.
Ekihiro Seki. David A. Brenner. Recent
advancement of molecular mechanisms of liver
fibrosis 2015; 1-7.
Lee YA1, Wallace MC, Friedman SL.
Pathobiology of liver fibrosis a translational
success story, Gut. 2015; 64(5):830-841.
Xu J, Liu X, Koyama Y, Wang P, Lan T, Kim
IG, Kim IH, Ma HY, Kisseleva T. The types of
hepatic myofibroblasts contributing to liver
fibrosis of different etiologies. Front Pharmacol.
Jul 22; 5:167.
Hinz B, Phan SH, Thannickal VJ, Galli A,
Bochaton-Piallat ML, Gabbiani G. The
myofibroblast: one function, multiple origins.
Am J Pathol. 2007 Jun;170(6):1807-16.
Xu J, Cong M, Park TJ, Scholten D, Brenner
DA, Kisseleva T. Contribution of bone
marrow-derived fibrocytes to liver fibrosis.
Hepatobiliary Surg Nutr. 2015 Feb; 4(1):34-47.
R. Bataller and D.A. Brenner. Liver fibrosis. J
Clin Invest 2005; 115:209-218.
S.L. Friedman: Hepatic fibrosis --overview.
Toxicology 2008; 254:120-129.
S.L. Friedman: Mechanisms of hepatic
fibrogenesis. Gastroenterology 2008; 134:
-1669.
Dooley S, Hamzavi J, Ciuclan L, Godoy P,
Ilkavets I, Ehnert S, Ueberham E,Gebhardt R,
Kanzler S, Geier A, Breitkopf K, Weng H,
Mertens PR.Hepatocyte-specific Smad7
expression attenuates TGF-beta-mediated
fibrogenesis and protects against liver damage.
Gastroenterology. 2008 Aug;135(2):642-59.
Wu BR, Zheng YL, Sang XL, Jin M, Wang
WZ, Zhang QS, Zhao SX, Kong L. Role of the
IGF-1/PI3K pathway and the molecular
mechanism of Fuzhenghuayu therapy in a
spontaneous recovery rat model of liver fibrosis.
Zhonghua Gan Zang Bing Za Zhi.2013 Sep;
(9):674-8.
Lee JD, Choi MA, Ro SW, Yang WI, Cho AE,
Ju HL, Baek S, Chung SI, Kang WJ, Yun M,
Park JH. Synergic chemoprevention with dietary
carbohydrate restriction and supplementation of
AMPK-activating phytochemicals: the role of
SIRT1. Eur J Cancer Prev. 2015 Mar 19.
Guo Y, Zhang Y, Zhang Q, Guo X, Zhang H,
Zheng G, Liu L. Insulin-like growth factor
binding protein-related protein 1 (IGFBPrP1)
contributes to liver inflammation and fibrosis via
activation of the ERK1/2 pathway. Hepatol Int.
Jan;9(1):130-41.
De Minicis S, Seki E, Uchinami H, Kluwe J,
Zhang Y, Brenner DA, Schwabe RF.
Gene expression profiles during hepatic stellate
cell activation in culture and in vivo.
Gastroenterology. 2007 May;132(5):1937-46.
W.E. Naugler, T. Sakurai, S. Kim, S. Maeda, K.
Kim, A.M. Elsharkawy, M. Karin. Gender
disparity in liver cancer due to sex differences in
MyD88-dependent IL-6 production. Science
; 317:21-124.
Seki E, De Minicis S, Gwak GY, Kluwe J,
Inokuchi S, Bursill CA, Llovet JM,Brenner DA,
Schwabe RF. CCR1 and CCR5 promote hepatic
fibrosis in mice. J Clin Invest. 2009
Jul;119(7):1858-70.
Marra F, Bertolani C. Adipokines in liver
diseases, Hepatology 2009 Sep; 50(3):957-69.
De Minicis S, Seki E, Oesterreicher C, Schnabl
B, Schwabe RF, Brenner DA.Reduced
nicotinamide adenine dinucleotide phosphate
oxidase mediates fibrotic and inflammatory
effects of leptin on hepatic stellate cells.
Hepatology. 2008 Dec;48(6):2016-26.
Zhao X, Fu J, Xu A, Yu L, Zhu J, Dai R, Su B,
Luo T, Li N, Qin W, Wang B,Jiang J, Li S, Chen
Y, Wang H. Gankyrin drives malignant transformation of chronic liver damage-mediated
fibrosis via the Rac1/JNK pathway. Cell Death
Dis. 2015 May 7;6:e1751.
Paik YH, Kim J, Aoyama T, De Minicis S,
Bataller R, Brenner DA. Role of NADPH
oxidases in liver fibrosis. Antioxid Redox Signal.
Jun 10;20(17):2854-72.
De Minicis S, Agostinelli L, Rychlicki C,
Sorice GP, Saccomanno S, Candelaresi C,
Giaccari A, Trozzi L, Pierantonelli I, Mingarelli
E, Marzioni M, Muscogiuri G,Gaggini M,
Benedetti A, Gastaldelli A, Guido M,
Svegliati-Baroni G. HCC development is
associated to peripheral insulin resistance in a
mouse model of NASH. PLoS One. 2014 May
;9(5):e97136.
Ziogas DC, Gras-Miralles B, Mustafa S, Geiger
BM, Najarian RM, Nagel JM, Flier SN, Popov
Y, Tseng YH, Kokkotou E.
Anti-melanin-concentrating hormone treatment
attenuates chronic experimental colitis and
fibrosis. Am J Physiol Gastrointest Liver
Physiol. 2013 May 15; 304(10):G876-84.
Jirouskova M, Zbodakova O, Gregor M,
Chalupsky K, Sarnova L, Hajduch M,Ehrmann J,
Jirkovska M, Sedlacek R. Hepatoprotective
effect of MMP-19 deficiency in a mouse model
of chronic liver fibrosis. PLoS One. 2012;
(10):e46271.
Nishizawa H, Takahashi M, Fukuoka H, Iguchi
G, Kitazawa R, Takahashi Y.GH-independent
IGF-I action is essential to prevent the
development of nonalcoholic steatohepatitis in a
GH-deficient rat model. Biochem Biophys Res
Commun. 2012 Jun 29;423(2):295-300.
Iwasa J, Shimizu M, Shiraki M, Shirakami Y,
Sakai H, Terakura Y, Takai K,Tsurumi H,
Tanaka T, Moriwaki H. Dietary supplementation
with branched-chain amino acids suppresses
diethylnitrosamine-induced liver tumorigenesis
in obese and diabetic C57BL/KsJ-db/db mice.
Cancer Sci. 2010 Feb; 101(2):460-7.
Ueberham E, Löw R, Ueberham U, Schönig K,
Bujard H, Gebhardt R. Conditional
tetracycline-regulated expression of TGF-beta1
in liver of transgenic mice leads to reversible
intermediary fibrosis. Hepatology. 2003 May;
(5):1067-78.
Czochra P, Klopcic B, Meyer E, Herkel J,
Garcia-Lazaro JF, Thieringer F,Schirmacher P,
Biesterfeld S, Galle PR, Lohse AW, Kanzler S.
Liver fibrosis induced by hepatic overexpression
of PDGF-B in transgenic mice. J Hepatol. 2006
Sep; 45(3):419-28.
Campbell JS, Hughes SD, Gilbertson DG,
Palmer TE, Holdren MS, Haran AC, Odell MM,
Bauer RL, Ren HP, Haugen HS, Yeh MM,
Fausto N. Platelet-derived growth factor C
induces liver fibrosis, steatosis, and
hepatocellular carcinoma. Proc Natl Acad Sci U
S A. 2005 Mar 1;102(9):3389-94.
Yoshiji H, Kuriyama S, Miyamoto Y,
Thorgeirsson UP, Gomez DE, Kawata M, Yoshii
J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani
T, Thorgeirsson SS, Fukui H.Tissue inhibitor of
metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model.
Hepatology. 2000 Dec;32(6):1248-54.
Popov Y, Patsenker E, Fickert P, Trauner M,
Schuppan D. Mdr2 (Abcb4)-/- mice
spontaneously develop severe biliary fibrosis via
massive dysregulation of pro-and antifibrogenic
genes. J Hepatol. 2005 Dec;43(6):1045-54.
Pikarsky E, Porat RM, Stein I, Abramovitch R,
Amit S, Kasem S, Gutkovich-Pyest E,
Urieli-Shoval S, Galun E, Ben-Neriah Y.
NF-kappaB functions as a tumour promoter in
inflammation-associated cancer. Nature. 2004
Sep 23; 431(7007):461-6.
Guo Y, Zhang Y, Zhang Q, Guo X, Zhang H,
Zheng G, Liu L. Insulin-like growth factor
binding protein-related protein 1 (IGFBPrP1)
contributes to liver inflammation and fibrosis via
activation of the ERK1/2 pathway. Hepatol Int.
Jan;9(1):130-41.
Zhang Y, Zhang QQ, Guo XH,et al.
IGFBPrP1induces liver fibrosis by inducing
hepatic stellate cell activation and hepatocyte
apoptosis via Smad3 signaling. World J
Gastroenterol 2014; 20(21):6523-33.
Fan Y, Fang X, Tajima A, Geng X,
Ranganathan S, Dong H, Trucco M,
SperlingMA.Evolution of hepatic steatosis to
fibrosis and adenoma formation inliver-specific
growth hormone receptor knockout mice. Front
Endocrinol (Lausanne). 2014 Dec 18; 5:218.
Ma H, Zhao XL, Wang XY, Xie XW, Han JC,
Guan WL, Wang Q, Zhu L, Pan XB, Wei
L.2',3'-cyclic nucleotide 3'-phosphodiesterases
inhibit hepatitis B virusreplication. PLoS One.
Nov 18;8(11):e80769.
Sokolović A, Rodriguez-Ortigosa CM,
Bloemendaal LT, Oude Elferink RP, Prieto J,
Bosma PJ. Insulin-like growth factor 1 enhances
bile-duct proliferation and fibrosis in Abcb4(-/-)
mice. Biochim Biophys Acta. 2013
Jun;1832(6):697-704.
Matz-Soja M, Aleithe S, Marbach E, Böttger J,
Arnold K, Schmidt-Heck W,Kratzsch J,
Gebhardt R. Hepatic Hedgehog signaling
contributes to the regulation of IGF1 and
IGFBP1 serum levels. Cell Commun Signal.
Feb 18; 12:11.
Guo Y, Zhang Y, Zhang Q, Guo X, Zhang H,
Zheng G, Liu L. Insulin-like growth factor
binding protein-related protein 1 (IGFBPrP1)
contributes to liver inflammation and fibrosis via
activation of the ERK1/2 pathway. Hepatol Int.
Jan; 9(1):130-41.
M.Binoux. The IGF system in metabolism
regulation. Diabete Metab.1995; 21:330-337.
Adams LA, Feldstein A, Lindor KD, Angulo P.
Nonalcoholic fatty liver disease among patients
with hypothalamic and pituitary dysfunction.
Hepatology. 2004Apr; 39(4):909-14.
Sumida Y, Yonei Y, Tanaka S, Mori K,
Kanemasa K, Imai S, Taketani H, Hara T,Seko
Y, Ishiba H, Okajima A, Yamaguchi K,
Moriguchi M, Mitsuyoshi H, YasuiK,Minami M,
Itoh Y. Lower levels of insulin-like growth factor-1 standard deviationscore are associated
with histological severity of non-alcoholic fatty
liver disease. Hepatol Res. 2014 Aug 28.
Cianfarani S, Inzaghi E, Alisi A, Germani D,
Puglianiello A, Nobili V. Insulin-like growth
factor-I and -II levels are associated with the
progressionof nonalcoholic fatty liver disease in
obese children. J Pediatr. 2014Jul; 165(1):92-8.
Khoshnood A, NasiriToosi M, Faravash MJ,
Esteghamati A, Froutan H, GhofraniH, Kalani
M, Miroliaee A, Abdollahi A, Yasir A. A survey
of correlation between insulin-like growth
factor-I (igf-I) levels and severity of liver
cirrhosis. Hepat Mon. 2013 Feb 23; 13(2):e6181.
Rehem RN, El-ShikhWM.Serum IGF-1, IGF-2
and IGFBP-3 as parameters in the assessment of
liver dysfunction in patients with hepatic cirrhosis
and in the diagnosis of hepatocellular carcinoma.
Hepatogastroenterology2011;
(107-108):949-954.
Shmueli E, Stewart M, Alberti KG, Record CO.
Growth hormone, insulin-like growth factor-1
and insulin resistance in cirrhosis. Hepatology.
Feb; 19(2):322-8.
Chan AC, Poon RT, Chok KS, Cheung TT,
Chan SC, Lo CM. Feasibility of laparoscopic
re-resection for patients with recurrent
hepatocellular carcinoma. World J Surg. 2014
May; 38(5):1141-6.
Stiedl P, McMahon R, Blaas L, et al.Growth
hormone resistance exacerbates
cholestasis-induced murine liver fibrosis,
Hepatology 2015; 61(2):613-26.
Liang LJ, Luo SM, Hu WJ, et al.Effects of amino
acid solution and recombinant human growth
hormone on growth hormone/insulin like growth
factor-1 axis in rats with liver cirrhosis,Zhonghua
Wai Ke Za Zhi 2005; 43(11):697-701.
Y.Takahashi, K.Growth hormone reverses
nonalcoholic steatohepatitis in a patient with
adult growth hormone deficiency,
Gastroenterology 2007; 132:938-943.
Patricia Stiedl,Robert McMahon, Leander
Blaas,et al.Growth Hormone Resistance
Exacerbates Cholestasis-Induced Murine Liver
Fibrosis, HEPATOLOGY, 2015; 61(2):615-623.
Growth hormone in liver fibrosis 2014
J.Flier, L.Underhill, D.Le Roith. Insulin-like
growth factors. New Engl.J.1997; 633-640.
Bonkowski MS, Pamenter RW, Rocha JS,
Masternak MM, Panici JA, Bartke A. Long-lived
growth hormone receptor knockout mice show a
delay in age-related changes of body composition
and bone characteristics. J Gerontol A Biol Sci
Med Sci. 2006; 61:562–567.
Egecioglu E, Andersson IJ, Bollano E, Palsdottir
V, Gabrielsson BG, KopchickJJ, Skott O, Bie P,
Isgaard J, Bohlooly-Y M, Bergström G, Wickman
A. Growthhormone receptor deficiency in mice
results in reduced systolic blood pressureand
plasma renin, increased aortic eNOS expression,
and altered cardiovascularstructure and function.
Am J Physiol Endocrinol Metab. 2007 May;
(5):E1418-25.
Guevara-Aguirre J, Balasubramanian P,
Guevara-Aguirre M, et al. Growth hormone
receptor deficiency is associated with a major
reductioninpro-agingsignaling,cancer,anddiabete
sinhumans. Sci Transl Med 2011; 3:70ra13
Fan Y, Menon RK, Cohen P, Hwang D, Clemens
T, DiGirolamo DJ, et al. Liver-specific deletion of
the growth hormone receptor reveals essential
role of growth hormone signaling in hepatic lipid
metabolism. J Biol Chem (2009)
(30):19937-44.
doi:10.1074/jbc.M109.014308
Sos BC, Harris C, Nordstrom SM, Tran JL,
Balázs M, Caplazi P, FebbraioM,Applegate MA,
Wagner KU, Weiss EJ. Abrogation of growth
hormone secretion rescues fatty liver in mice with
hepatocyte-specific deletion of JAK2. J Clin
Invest.2011 Apr; 121(4):1412-23.
Edward O. List, Darlene E. Berryman, Kevin
Funk, Adam Jara, Bruce Kelder, Feiya Wang,
Michael B. Stout, Xu Zhi, Liou Sun, Thomas A.
White, Nathan K. LeBrasseur, Tamara
Pirtskhalava, Tamara Tchkonia, Elizabeth A.
Jensen, Wenjuan Zhang, Michal M. Masternak,
James L. Kirkland, Richard A. Miller, Andrzej
Bartke, John J. Kopchick, et al. Liver-Specific
GH Receptor Gene-Disrupted (LiGHRKO) Mice
Have Decreased Endocrine IGF-I, Increased
Local IGF-I, and Altered Body Size, Body
Composition, and Adipokine Profiles,
Endocrinology, May 2014, 155(5):1793-1805.
Escribano O, Guillen C, Nevado C,
Gomez-Hernandez A, Kahn CR, Benito M.
Beta-cell hyperplasia induced by hepatic insulin
resistance: role of a liver-pancreas endocrine axis
through insulin receptor A isoform. Diabetes
(2009) 58(4):820-8.
Malaguarnera R, Belfiore A. The insulin
receptor: a new target for cancer therapy. Front
Endocrinol (Lausanne). 2011 Dec 6; 2:93.
Yong Fan1, Xin Fang, AsakoTajima, Xuehui
Geng, Sarangarajan Ranganathan, Henry Dong,
MassimoTrucco, MarkA. Sperling, et
al.Evolution of hepatic steatosis to fibrosis and
adenoma formation in liver-specific growth
hormone receptor knockout mice, Endocrinology 2014; 5:218.
Enguita-Germán M, Fortes P. Targeting the
insulin-like growth factor pathway in
hepatocellular carcinoma. World J Hepatol. 2014
Oct 27; 6(10):716-37.
Annunziata M, Granata R, Ghigo E.The IGF
system.Acta Diabetol 2011; 48:1-9.
Juan E Puche, Castilla-Cortázar.Human
conditions of insulin-like growth factor-I (IGF-I)
deficiency. Journal of Translational Medicine
, 10:224-230
Bender SB, McGraw AP, Jaffe IZ, Sowers JR.
Mineralocorticoid receptor-mediated vascular
insulin resistance: an early contributor to
diabetes-related vascular disease? Diabetes. 2013
Feb; 62(2):313-9.
Baker J, Liu JP, Robertson EJ, Efstratiadis A.
Role of insulin-like growth factors in embryonic
and postnatal growth. Cell. 1993 Oct 8;
(1):73-82.
Cao Y, Nimptsch K, Shui IM, Platz EA, Wu K,
Pollak MN, Kenfield SA, Stampfer MJ,
Giovannucci EL. Prediagnostic plasma IGFBP-1,
IGF-1 and risk of prostate cancer. Int J Cancer.
May 15;136(10):2418-26.
Erarslan E, Coşkun Y, Türkay C, Köktener A,
Aydoğan T. IGF-I levels and visceral fat
accumulation in colonic neoplasia. Clin Res
Hepatol Gastroenterol.2014 Feb; 38(1):99-105.
Rinaldi S, Biessy C, Hernandez M, Lesueur F,
dos-Santos-Silva I, Rice MS,Lajous M,
Lopez-Ridaura R, Torres-Mejía G, Romieu I.
Circulating concentrations of insulin-like growth
factor-I, insulin-like growth factor-binding
protein-3,genetic polymorphisms and
mammographic density in premenopausal
Mexican women: results from the ESMaestras
cohort. Int J Cancer. 2014 Mar 15;
(6):1436-44.
Douglas JB, Silverman DT, Pollak MN, Tao Y,
Soliman AS, Stolzenberg-Solomon RZ. Serum
IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3
molar ratio and risk of pancreatic cancer in the
prostate, lung, colorectal and ovarian cancer
screening trial. Cancer Epidemiol Biomarkers
Prev. 2010 Sep; 19(9):2298-306.
Fernández-Rodriguez CM, Prada I, Andrade A,
Moreiras M, Guitián R, Aller R,Lledó JL, Cacho
G, Quiroga J, Prieto J. Disturbed synthesis of
insulinlike growth factor I and its binding
proteins may influence renal function changes in
liver cirrhosis. Dig Dis Sci. 2001
Jun;46(6):1313-20.
Chun YS, Huang M, Rink L, Von Mehren M.
Expression levels of insulin-like growth factors
and receptors in hepatocellular carcinoma: a
retrospective study. World J Surg Oncol. 2014
Jul 22; 12:231.
Cianfarani S, Inzaghi E, Alisi A, Germani D,
Puglianiello A, Nobili V.Insulin-like growth
factor-I and -II levels are associated with the
progression of nonalcoholic fatty liver disease in
obese children. J Pediatr. 2014 Jul;165(1):92-8.
Hribal ML, Procopio T, Petta S, Sciacqua A,
Grimaudo S, Pipitone RM, Perticone F, Sesti G.
Insulin-like growth factor-I, inflammatory
proteins, and fibrosis in subjects with
nonalcoholic fatty liver disease. J Clin
Endocrinol Metab. 2013 Feb; 98(2):E304-8.
Ichikawa T, Nakao K, Hamasaki K, Furukawa
R, Tsuruta S, Ueda Y, Taura N,Shibata H,
Fujimoto M, Toriyama K, Eguchi K. Role of
growth hormone, insulin-like growth factor 1 and
insulin-like growth factor-binding protein 3 in
development of non-alcoholic fatty liver disease.
Hepatol Int. 2007 Jun;1(2):287-94.
Khoshnood A, Nasiri Toosi M, Faravash MJ,
Esteghamati A, Froutan H, Ghofrani H, Kalani
M, Miroliaee A, Abdollahi A, Yasir A. A survey
of correlation between insulin-like growth
factor-I (igf-I) levels and severity of liver
cirrhosis. Hepat Mon. 2013 Feb 23;13(2):e6181.
Yongwen Li, RAJAR Volume 1 Issue 8 Sept 2015 302
Mazziotti G, Sorvillo F, Morisco F, Carbone A,
Rotondi M, Stornaiuolo G,Precone DF, Cioffi M,
Gaeta GB, Caporaso N, Carella C. Serum
insulin-like growth factor I evaluation as a useful
tool for predicting the risk of developing
hepatocellular carcinoma in patients with
hepatitis C virus-related cirrhosis: a prospective
study. Cancer. 2002 Dec 15;95(12):2539-45.
Nishizawa H, Takahashi M, Fukuoka H, Iguchi
G, Kitazawa R, Takahashi Y.GH-independent
IGF-I action is essential to prevent the
development of nonalcoholic steatohepatitis in a
GH-deficient rat model. Biochem Biophys Res
Commun. 2012 Jun 29; 423(2):295-300.
Sumida Y, Yonei Y, Tanaka S, Mori K,
Kanemasa K, Imai S, Taketani H, Hara T,Seko
Y, Ishiba H, Okajima A, Yamaguchi K,
Moriguchi M, Mitsuyoshi H, Yasui K,Minami
M, Itoh Y. Lower levels of insulin-like growth
factor-1 standard deviation score are associated
with histological severity of non-alcoholic fatty
liver disease. Hepatol Res. 2014 Aug 28.
Colak Y, Senates E, Ozturk O, Yilmaz Y,
Zemheri E, Yilmaz Enc F, Ulasoglu C,Aksaray
S, Bozbeyoglu SG, Kiziltas S, Kurdas OO,
Tuncer I. Serum concentrations of human
insulin-like growth factor-1 and levels of
insulin-like growth factor-binding protein-5 in
patients with nonalcoholic fatty liver disease:
association with liver histology. Eur J
Gastroenterol Hepatol. 2012 Mar; 24(3):255-61.
Colakoğlu O, Taşkiran B, Colakoğlu G,
Kizildağ S, Ari Ozcan F, Unsal B. Serum insulin
like growth factor-1 (IGF-1) and insulin like
growth factor binding protein-3 (IGFBP-3) levels
in liver cirrhosis. Turk J Gastroenterol. 2007
Dec; 18(4):245-9.
Dehghani SM, Karamifar H, Hamzavi SS,
Haghighat M, Malek-Hosseini SA. Serum
insulinlike growth factor-1 and its binding
protein-3 levels in children with cirrhosis waiting
for a liver transplant. Exp Clin Transplant. 2012
Jun;10(3):252-7.
Rehem RN, El-Shikh WM. Serum IGF-1,
IGF-2 and IGFBP-3 as parameters in the
assessment of liver dysfunction in patients with
hepatic cirrhosis and in the diagnosis of
hepatocellular carcinoma.
Hepatogastroenterology. 2011 May-Jun;
(107-108):949-54.
Cianfarani S, Inzaghi E, Alisi A, Germani D,
Puglianiello A, Nobili V.Insulin-like growth
factor-I and -II levels are associated with the
progression of nonalcoholic fatty liver disease in
obese children. J Pediatr. 2014 Jul;165(1):92-8.
Assy N, Pruzansky Y, Gaitini D, Shen Orr Z,
Hochberg Z, Baruch Y. Growth
hormone-stimulated IGF-1 generation in cirrhosis
reflects hepatocellular dysfunction. J Hepatol.
Jul; 49(1):34-42.
Lorenzo-Zúñiga V, Bartolí R, Masnou H,
Montoliu S, Morillas RM, Planas R.Serum
concentrations of insulin-like growth factor-I
(igf-I) as a marker of liver fibrosis in patients
Yongwen Li, RAJAR Volume 1 Issue 8 Sept 2015 303
with chronic hepatitis C. Dig Dis Sci. 2007
Nov;52(11):3245-50.
Morali G, Shitrit AB, Eran M, Freier S, Reinus
C, Braverman D. Hepatic production of
insulin-like growth factors in normal and
diseased liver.Hepatogastroenterology. 2005
Sep-Oct;52(65):1511-5.
Kaseb AO, Morris JS, Hassan MM, Siddiqui
AM, Lin E, Xiao L, Abdalla EK,Vauthey JN,
Aloia TA, Krishnan S, Abbruzzese JL. Clinical
and prognostic implications of plasma
insulin-like growth factor-1 and vascular
endothelial growth factor in patients with
hepatocellular carcinoma. J Clin Oncol. 2011 Oct
; 29(29):3892-9.
Chen JW, Nielsen MF, Caumo A, Vilstrup H,
Christiansen JS, Frystyk J. Changes in bioactive
IGF-I and IGF-binding protein-1 during an oral
glucose tolerancetest in patients with liver
cirrhosis. Eur J Endocrinol. 2006
Aug;155(2):285-92.
Kaseb AO, Morris JS, Hassan MM, Siddiqui
AM, Lin E, Xiao L, Abdalla EK,Vauthey JN,
Aloia TA, Krishnan S, Abbruzzese JL. Clinical
and prognostic implications of plasma
insulin-like growth factor-1 and vascular
endothelial growth factor in patients with
hepatocellular carcinoma. J Clin Oncol. 2011 Oct
; 29(29):3892-9.
Cho E, Kim HC, Lee JH, Jeong-Ju Yoo, Choi
WM, Cho YY, Lee MJ, Cho Y, Lee DH,Lee YB,
Yu SJ, Kim YJ, Yoon JH, Chung JW, Kim CY,
Lee HS. Serum insulin-like growth factor-1
predicts disease progression and survival in
patients with hepatocellular carcinoma who
undergo transarterial chemoembolization. PLoS
One.2014 Mar 4; 9(3):e90862.
Shao YY, Huang CC, Lin SD, Hsu CH, Cheng
AL. Serum insulin-like growth factor-1 levels
predict outcomes of patients with advanced
hepatocellular carcinoma receiving
antiangiogenic therapy. Clin Cancer Res. 2012
Jul 15; 18(14):3992-7.
Hoshida Y, Villanueva A, Kobayashi M, Peix
J, Chiang DY, Camargo A, Gupta S,Moore J,
Wrobel MJ, Lerner J, Reich M, Chan JA,
Glickman JN, Ikeda K, Hashimoto M, Watanabe
G, Daidone MG, Roayaie S, Schwartz M, Thung
S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix
J, Friedman SL, Kumada H, Llovet JM, Golub
TR. Gene expression in fixed tissues and
outcome in hepatocellular carcinoma. N Engl J
Med. 2008 Nov 6; 359(19):1995-2004.
Villanueva A, Hoshida Y, Toffanin S,
Lachenmayer A, Alsinet C, Savic R,Cornella H,
Llovet JM. New strategies in hepatocellular
carcinoma: genomic prognostic markers. Clin
Cancer Res. 2010 Oct 1; 16(19):4688-94.
Riedemann J, Macaulay VM. IGF1R signaling
and its inhibition. Endocr Relat Cancer 2006; 1:
-43.
Pollak MN, Schernhammer ES, Hankinson SE.
Insulin-like growth factors and neoplasia. Nat
Rev Cancer 2004; 4: 505-518.
Yongwen Li, RAJAR Volume 1 Issue 8 Sept 2015 304
Jennifer Wu, Andrew X Zhu. Targeting
insulin-like growth factor axis in hepatocellular
carcinoma. Journal of Hematology & Oncology
, 4:30.
Vatten LJ, Nilsen ST, Odegård RA,
Romundstad PR, Austgulen R. Insulin-like
growth factor I and leptin in umbilical cord
plasma and infant birth size atterm. Pediatrics.
Jun; 109(6):1131-5.
Vigneri P, Frasca F, Sciacca L. Diabetes and
cancer. Endocr Relat Cancer 2009; 16:
-1123.
Yulyana Y, Ho IA, Sia KC, Newman JP, Toh
XY, Endaya BB, Chan JK, Gnecchi M,Huynh H,
Chung AY, Lim KH, Leong HS, Iyer NG, Hui
KM, Lam PY. Paracrine factors of human fetal
MSCs inhibit liver cancer growth through
reduced activation of IGF-1R/PI3K/Akt
signaling. Mol Ther. 2015 Apr;23(4):746-56.
Sun, B and Karin, M. NF-kappaB signaling,
liver disease and hepatoprotective agents.
Oncogene 2008; 27: 6228-6244.
Aleem E, Nehrbass D, Klimek F, Mayer D,
Bannasch P. Upregulation of the insulin receptor
and type I insulin-like growth factor receptor are
early events in hepatocarcinogenesis. Toxicol
Pathol 2011; 39: 524-543.
Kasprzak A, Adamek A. The insulin-like
growth factor (IGF) signaling axis and hepatitis
C virus-associated carcinogenesis (review). Int J
Oncol 2012; 41: 1919-1931.
Stefano JT, Correa-Giannella ML, Ribeiro CM,
Alves VA, Massarollo PC, Machado MC,
Giannella-Neto D. Increased hepatic expression
of insulin-like growth factor-I receptor in chronic
hepatitis C. World J Gastroenterol. 2006 Jun
;12(24):3821-8.
Jeng JE1, Chuang LY, Chuang
WL.Insulin-like growth factor II in
hepatocellular carcinoma, Biomark Med 2007;
(2):261-271.
Chun YS, Huang M, Rink L, Von Mehren M.
Expression levels of insulin-like growth factors
and receptors in hepatocellular carcinoma: a
retrospective study. World J Surg Oncol. 2014
Jul 22;12:231. doi: 10.1186/1477-7819-12-231.
Nussbaum T, Samarin J, Ehemann V,
Bissinger M, Ryschich E, Khamidjanov A, Yu
X, Gretz N, Schirmacher P, Breuhahn K.
Autocrine insulin-like growth factor-II
stimulation of tumor cell migration is a
progression step in human hepatocarcinogenesis.
Hepatology. 2008 Jul; 48(1):146-56.
O’Dell SD, Day IN. Insulin-like growth factor
II (IGF-II). Int J Biochem Cell Biol 1998; 30:
-771.
Sussenbach JS, Steenbergh PH, Holthuizen P.
Structure and expression of the human
insulin-like growth factor genes. Growth Regul.
Mar;2(1):1-9.
Zhang Q, Tally M, Larsson O, Kennedy RT,
Huang L, Hall K, Berggren PO.Insulin-like
growth factor II signaling through the
Yongwen Li, RAJAR Volume 1 Issue 8 Sept 2015 305
insulin-like growth factor
II/mannose-6-phosphate receptor promotes
exocytosis in insulin-secreting cells.Proc Natl
Acad Sci U S A. 1997 Jun 10;94(12):6232-7.
Zhang Q, Berggren PO, Larsson O, Hall K,
Tally M. Insulin-like growth factor II inhibits
glucose-induced insulin exocytosis. Biochem
Biophys Res Commun. 1998 Feb 4;
(1):117-21.
Sacco A, Morcavallo A, Pandini G, Vigneri R,
Belfiore A. Differential signaling activation by
insulin and insulin-like growth factors I and II
upon binding to insulin receptor isoform A.
Endocrinology. 2009 Aug;150(8):3594-602.
Sciacca L, Prisco M, Wu A, Belfiore A,
Vigneri R, Baserga R. Signaling differences from
the A and B isoforms of the insulin receptor (IR)
in 32D cells in the presence or absence of IR
substrate-1. Endocrinology. 2003
Jun;144(6):2650-8.
Denley A, Wallace JC, Cosgrove LJ, Forbes
BE. The insulin receptor isoform exon 11-
(IR-A) in cancer and other diseases: a review.
Horm Metab Res. 2003
Nov-Dec;35(11-12):778-85.
Williams C, Hoppe HJ, Rezgui D, Strickland
M, Forbes BE, Grutzner F, Frago S,Ellis RZ,
Wattana-Amorn P, Prince SN, Zaccheo OJ,
Nolan CM, Mungall AJ, Jones EY,Crump MP,
Hassan AB. An exon splice enhancer primes
IGF2:IGF2R binding site structure and function
evolution. Science. 2012 Nov 30;
(6111):1209-13.
Vashisth H, Abrams CF. All-atom structural
models for complexes of insulin-like growth
factors IGF1 and IGF2 with their cognate
receptor. J Mol Biol. 2010 Jul 16; 400(3):645-58.
Gary-Bobo M, Nirdé P, Jeanjean A, Morère A,
Garcia M. Mannose 6-phosphate receptor
targeting and its applications in human diseases.
Curr Med Chem.2007; 14(28):2945-53.
Clairmont KB, Czech MP. Extracellular
release as the major degradative pathway of the
insulin-like growth factor II/mannose
-phosphate receptor. J Biol Chem.1991 Jul 5;
(19):12131-4.
Jeyaratnaganthan N, Grønbaek H,
Holland-Fischer P, Espelund U, Chen
JW,Flyvbjerg A, Vilstrup H, Frystyk J. Ascites
from patients with alcoholic liver cirrhosis
contains higher IGF-I bioactivity than serum.
Clin Endocrinol (Oxf).2010 May; 72(5):625-32.
Tsai JF, Jeng JE, Chuang LY, You HL, Ho
MS, Lai CS, Wang LY, Hsieh MY, Chen SC,
Chuang WL, Lin ZY, Yu ML, Dai CY. Serum
insulin-like growth factor-II and
alpha-fetoprotein as tumor markers of
hepatocellular carcinoma. Tumour Biol. 2003
Nov-Dec; 24(6):291-8.
Tsai JF, Jeng JE, Chuang LY, You HL, Wang
LY, Hsieh MY, Chen SC, Chuang WL,Lin ZY,
Yu ML, Dai CY. Serum insulin-like growth
factor-II as a serologic marker of small
hepatocellular carcinoma. Scand J Gastroenterol.
Jan; 40(1):68-75.
Yongwen Li, RAJAR Volume 1 Issue 8 Sept 2015 306
Ou JM, Lian WS, Qiu MK, Dai YX, Dong Q,
Shen J, Dong P, Wang XF, Liu YB, Quan ZW,
Fei ZW. Knockdown of IGF2R suppresses
proliferation and induces apoptosis in
hemangioma cells in vitro and in vivo. Int J
Oncol. 2014 Sep; 45(3):1241-9.
Klopfleisch R, Hvid H, Klose P, da Costa A,
Gruber AD. Insulin receptor is expressed in
normal canine mammary gland and benign
adenomas but decreased in metastatic canine
mammary carcinomas similar to human breast
cancer. Vet Comp Oncol. 2010
Dec;8(4):293-301.
Kalla Singh S, Tan QW, Brito C, De León M,
De León D. Insulin-like growth factors I and II
receptors in the breast cancer survival disparity
among African-American women. Growth Horm
IGF Res. 2010 Jun; 20(3):245-54.
180 O’Gorman DB, Costello M, Weiss J, Firth
SM, Scott CD. Decreased insulin-like growth
factor-II/mannose 6-phosphate receptor
expression enhances tumorigenicity in JEG-3
cells. Cancer Res 1999; 59: 5692-5694.
Chen Z, Ge Y, Landman N, Kang JX.
Decreased expression of the mannose
-phosphate/insulin-like growth factor-II
receptor promotes growth of human breast
cancer cells. BMC Cancer 2002; 2: 18.
Hu CK, McCall S, Madden J, Huang H,
Clough R, Jirtle RL, Anscher MS. Loss of
heterozygosity of M6P/IGF2R gene is an early
event in the development of prostate cancer.
Prostate Cancer Prostatic Dis. 2006; 9(1):62-7.
Klopfleisch R, Hvid H, Klose P, da Costa A,
Gruber AD. Insulin receptor is expressed in
normal canine mammary gland and benign
adenomas but decreased in metastatic canine
mammary carcinomas similar to human breast
cancer. Vet Comp Oncol. 2010 Dec;
(4):293-301.
Puxbaum V, Nimmerfall E, Bäuerl C, Taub N,
Blaas PM, Wieser J, Mikula M,Mikulits W, Ng
KM, Yeoh GC, Mach L. M6P/IGF2R modulates
the invasiveness of liver cells via its capacity to
bind mannose 6-phosphate residues. J Hepatol.
Aug; 57(2):337-43.
Probst OC, Puxbaum V, Svoboda B, Leksa V,
Stockinger H, Mikula M, Mikulits W, Mach L.
The mannose 6-phosphate/insulin-like growth
factor II receptor restricts the tumourigenicity
and invasiveness of squamous cell carcinoma
cells. Int J Cancer. 2009 Jun 1;124(11):2559-67.
Li J, Sahagian GG. Demonstration of tumor
suppression by mannose 6-phosphate/insulin-like
growth factor 2 receptor. Oncogene 2004; 23:
-9368.
Martin-Kleiner I, Gall Troselj K.
Mannose-6-phosphate/ insulin-like growth
factor 2 receptor (M6P/IGF2R) in
carcinogenesis. Cancer Lett 2010; 289: 11-22.
Han YL, Guo P, Sun MY, Guo L, Luan B,
Kang J, Yan CH, Li SH. Secreted CREG inhibits
cell proliferation mediated by mannose
-phosphate/insulin-like growth factor II
receptor in NIH3T3 fibroblasts. Genes Cells
; 13: 977-986.
Yongwen Li, RAJAR Volume 1 Issue 8 Sept 2015 307
Burger AM, Leyland-Jones B, Banerjee K,
Spyropoulos DD, Seth AK. Essential roles of
IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J
Cancer. 2005 Jul; 41(11):1515-27.
Murphy LJ. Insulin-like growth factor-binding
proteins: functional diversity or redundancy? J
Mol Endocrinol. 1998 Oct;21(2):97-107.
P.Bang. Serum proteolysis of IGFBP-3, Prog,
Growth Factor Res.1995; 6:285-292.
Kerstin Brismar, Moira S.Lewitt.The IGF and
IGFBP system in insulin Resistance and
Diabetes Mellitus. IGF nutr. Heal.Dis. Houston,
M. Sue, Holly, Jeffrey M.P., Feldman, Eva L.
Humana Press 2004;251-271.
K. Brismar, A.Hilding, B.lingdgren.Regulation
of IGFBP-1 in humans Prog. Growth Factor Res
; 6:449-456.
J.Frystyk. The Effect of Oral Glucose on Serum
Free Insulin-like Growth Factor-1 and -2 in
Healthy Adults. J. Clin. Endocrinol.
Metab.1997; 82(9): 3124-3127.
J.I.Jones, A.Gockerman, W.H.Busby.
Insulin-like growth factor-binding protein 1
stimulates cell migration and binds to the alpha 5
beta 1 intergrin by means of its
Arg-Gly-Aspsequence,Proc.Natl.Acad.Sci.U.S.
A.,1993;90:10553-10557.
Dai B, Ruan B, Wu J, Wang J, Shang R, Sun
W, Li X, Dou K, Wang D, Li Y.Insulin-like
growth factor binding protein-1 inhibits cancer
cell invasion and is associated with poor
prognosis in hepatocellular carcinoma. Int J Clin
Exp Pathol. 2014 Aug 15; 7(9):5645-54.
Gong Y, Cui L, Minuk GY. The expression of
insulin-like growth factor binding proteins in
human hepatocellular carcinoma. Mol Cell
Biochem. 2000 Apr; 207(1-2):101-4.
Gnainsky Y, Spira G, Paizi M, Bruck R,
Nagler A, Genina O, Taub R, Halevy O,Pines M.
Involvement of the tyrosine phosphatase early
gene of liver regeneration (PRL-1) in cell cycle
and in liver regeneration and fibrosis effect of
halofuginone. Cell Tissue Res. 2006 Jun;
(3):385-94.
Jeyaratnaganthan N, Grønbaek H,
Holland-Fischer P, Espelund U, Chen
JW,Flyvbjerg A, Vilstrup H, Frystyk J. Ascites
from patients with alcoholic liver cirrhosis
contains higher IGF-I bioactivity than serum.
Clin Endocrinol (Oxf).2010 May; 72(5):625-32.
Nedic O, Malenkovic V, Dukanovic B,
Baricevic I. Association of elevated IGFBP-1
with increased IGF-II concentration in patients
with carcinoma of the liver. Int J Biol Markers.
Oct-Dec; 23(4):225-30.
Pollak M. Insulin-like growth factor signaling
in neoplasia.Nature Rev Cancer 2008;
:915-928.
So AI, Levitt RJ, Eigl B, Fazli L, Muramaki
M, Leung S, Cheang MC, Nielsen TO,Gleave M,
Pollak M. Insulin-like growth factor binding
protein-2 is a novel therapeutic target associated
Yongwen Li, RAJAR Volume 1 Issue 8 Sept 2015 308
with breast cancer. Clin Cancer Res. 2008 Nov 1;
(21):6944-54.
Yau SW, Azar WJ, Sabin MA, Werther GA,
Russo VC. IGFBP-2 - taking the lead in growth,
metabolism and cancer. J Cell Commun Signal.
Jun; 9(2):125-42.
Pickard A, McCance DJ. IGF-Binding Protein
-Oncogene or Tumor Suppressor? Front
Endocrinol (Lausanne). 2015 Feb 27; 6:25.
Yau SW, Azar WJ, Sabin MA, Werther GA,
Russo VC. IGFBP-2 - taking the lead in growth,
metabolism and cancer. J Cell Commun Signal.
Jun; 9(2):125-42.
Li N, Long Y, Fan X, Liu H, Li C, Chen L,
Wang Z. Proteomic analysis of differentially
expressed proteins in hepatitis B virus-related
hepatocellular carcinoma tissues. J Exp Clin
Cancer Res. 2009 Aug 28; 28:122.
Monzavi R, Cohen P. IGFs and IGFBPs: role
in health and disease. Best Pract Res Clin
Endocrinol Metab. 2002 Sep; 16(3):433-47.
Luo SM, Tan WM, Deng WX, Zhuang SM,
Luo JW. Expression of albumin, IGF-1,IGFBP-3
in tumor tissues and adjacent non-tumor tissues
of hepatocellular carcinoma patients with
cirrhosis. World J Gastroenterol. 2005 Jul 21;
(27):4272-6.
Ronsoni MF, Lazzarotto C, Fayad L, Silva
MC, Nogueira CL, Bazzo ML, Narciso-Schiavon
JL, Dantas-Corrêa EB, Schiavon Lde L. IGF-I
and IGFBP-3 serum levels in patients
hospitalized for complications of liver cirrhosis.
Ann Hepatol. 2013 May-Jun; 12(3):456-63.
Hanafusa T, Yumoto Y, Nouso K,
Nakatsukasa H, Onishi T, Fujikawa T, Taniyama
M, Nakamura S, Uemura M, Takuma Y, Yumoto
E, Higashi T, Tsuji T. Reduced expression of
insulin-like growth factor binding protein-3 and
its promoter hypermethylation in human
hepatocellular carcinoma. Cancer Lett. 2002 Feb
; 176(2):149-58.
Aleem E, Elshayeb A, Elhabachi N, Mansour
AR, Gowily A, Hela A. Serum IGFBP-3 is a
more effective predictor than IGF-1 and IGF-2
for the development of hepatocellular carcinoma
in patients with chronic HCV infection. Oncol
Lett. 2012 Mar; 3(3):704-712.
Aleem E, Elshayeb A, Elhabachi N, Mansour
AR, Gowily A, and Hela A. Serum IGFBP-3 is a
more effective predictor than IGF-1 and IGF-2
for the development of hepatocellular carcinoma
in patients with chronic HCV infection. Oncol
Lett. 2012 Mar; 3(3):704-712.
Y.Yamanaka,E.M.Wilson,R.G.Rosenfeld.CEL
L BIOLOGY AND METABOLISM: inhibition
of insulin Receptor Activation by insulin-like
Growth Factor binding proteins.J.Biol
Chem.1997;275:39(39):146-151.
Honda Y, Landale EC, Strong DD, Baylink
DJ, Mohan S. Recombinant synthesis of
insulin-like growth factor-binding protein-4
(IGFBP-4): Development, validation, and
application of a radioimmunoassay for IGFBP-4
Yongwen Li, RAJAR Volume 1 Issue 8 Sept 2015 309
in human serum and otherbiological fluids. J Clin
Endocrinol Metab. 1996 Apr; 81(4):1389-96.
Wex H, Ahrens D, Hohmann B, Redlich A,
Mittler U, Vorwerk P. Insulin-like growth
factor-binding protein 4 in children with acute
lymphoblastic leukemia.Int J Hematol. 2005
Aug;82(2):137-42.
Wegmann BR, Schöneberger HJ, Kiefer PE,
Jaques G, Brandscheid D, Havemann
K.Molecular cloning of IGFBP-5 from SCLC
cell lines and expression of IGFBP-4,IGFBP-5
and IGFBP-6 in lung cancer cell lines and
primary tumours. Eur J Cancer. 1993; 29A
(11):1578-84.
Pavelić J, Pavelić L, Karadza J, Krizanac S,
Unesić J, Spaventi S, Pavelić K. Insulin-like
growth factor family and combined antisense
approach in therapy of lung carcinoma. Mol
Med. 2002 Mar; 8(3):149-57.
Pekonen F, Nyman T, Ilvesmaki V. Insulin like
growth factor binding proteins in human breast
cancer tissue. Cancer Res 1992; 52:5204-5207.
Michell NP, Langman MJ, Eggo MC.
Insulin-like growth factors and their binding
proteins in human colonocytes: preferential
degradation of insulin-like growth factor binding
protein 2 in colonic cancers. Br J Cancer. 1997;
(1):60-6.
Bachrach LK, Nänto-Salonen K, Tapanainen P,
Rosenfeld RG, Gargosky SE.Insulin-like growth
factor binding protein production in human
follicular thyroid carcinoma cells. Growth Regul.
Jun; 5(2):109-18.
Mita K, Zhang Z, Ando Y, Toyama T,
Hamaguchi M, Kobayashi S, Hayashi S, Fujii Y,
Iwase H, Yamashita H .Prognostic significance of
insulin-like growth factor binding protein
(IGFBP)-4 and IGFBP-5 expression in breast
cancer. Jpn J Clin Oncol 2007; 37:575-582.
Sato H, Sakaeda M, Ishii J, Kashiwagi K,
Shimoyamada H, Okudela K, Tajiri M,Ohmori
T, Ogura T, Woo T, Masuda M, Hirata K,
Kitamura H, Yazawa T. Insulin-like growth
factor binding protein-4 gene silencing in lung
adenocarcinomas. Pathol Int. 2011 Jan;
(1):19-27.
Contois LW, Akalu A, Caron JM, Tweedie E,
Cretu A, Henderson T, Liaw L,Friesel R, Vary
C, Brooks PC. Inhibition of tumor-associated
αvβ3 integrin regulates the angiogenic switch by
enhancing expression of IGFBP-4 leading to
reduced melanoma growth and angiogenesis in
vivo. Angiogenesis. 2015 Jan; 18(1):31-46.
Clemmons DR. Use of mutagenesis to probe
IGF-binding protein structure/function
relationships. Endocr Rev 2001; 22: 800-817.
Duan C, Xu Q. Roles of insulin-like growth
factor (IGF) binding proteins in regulating IGF
actions. Gen Comp Endocrinol 142: 44–52, 2005.
Firth SM, Baxter RC. Cellular actions of the
insulin-like growth factor binding proteins.
Endocr Rev 2002; 23: 824-854.
Yongwen Li, RAJAR Volume 1 Issue 8 Sept 2015 310
Damon SE, Maddison L, Ware JL, Plymate
SR. Overexpression of an inhibitory insulin-like
growth factor binding protein (IGFBP),
IGFBP-4, delays onset of prostate tumor
formation. Endocrinology. 1998 Aug;
(8):3456-64.
Durai R, Yang SY, Seifalian AM, Goldspink
G, Winslet MC. Role of insulin-like growth
factor binding protein-4 in prevention of colon
cancer. World J Surg Oncol. 2007 Nov 7; 5:128.
Ueno K, Hirata H, Majid S, Tabatabai ZL,
Hinoda Y, Dahiya R. IGFBP-4 activates the
Wnt/beta-catenin signaling pathway and induces
M-CAM expression in human renal cell
carcinoma. Int J Cancer. 2011 Nov 15;
(10):2360-9.
Praveen Kumar VR, Sehgal P, Thota B, Patil
S, Santosh V, Kondaiah P. Insulin like growth
factor binding protein 4 promotes GBM
progression and regulates key factors involved in
EMT and invasion. J Neurooncol. 2014 Feb;
(3):455-64.
Praveen Kumar VR, Sehgal P, Thota B, Patil
S, Santosh V, Kondaiah P. Insulin like growth
factor binding protein 4 promotes GBM
progression and regulates key factors involved in
EMT and invasion. J Neurooncol. 2014 Feb;
(3):455-64.
Demori I, Balocco S, Voci A, Fugassa E.
Increased insulin-like growth factor binding
protein-4 expression after partial hepatectomy in
the rat. Am J Physiol Gastrointest Liver Physiol.
mar; 278(3):G384-9.
Maeda H, Yonou H, Yano K, Ishii G, Saito S,
Ochiai A. Prostate-specific antigen enhances
bioavailability of insulin-like growth factor by
degrading insulin-like growth factor binding
protein 5. Biochem Biophys Res Commun. 2009
Apr 10; 381(3):311-6.
Feghali, C.A., Wright, T.M. Identification of
multiple, differentially expressed messenger
RNAs in dermal fibroblasts from patients with
systemic sclerosis. Arthritis Rheum 1999;
:1451-1457.
Pilewski, J.M., Liu, L., Henry, A.C., Knauer,
A.V. and Feghali-Bostwick, C.A. Insulin-like
growth factor binding proteins 3 and 5 are
overexpressed in idiopathic pulmonary fibrosis
and contribute to extracellular matrix deposition.
Am. J. Pathol 2005; 166:399-407.
Yasuoka, H., Jukic, D.M., Zhou, Z., Choi, A.M.
, Feghali-Bostwick, C.A. Insulin-like growth
factor binding protein 5 induces skin fibrosis: a
novel murine model for dermal fibrosis. Arthritis
Rheum 2006; 54:3001-3010.
Yasuoka, H., Zhou, Z., Pilewski, J.M., Oury,
T.D., Choi, A.M. , Feghali-Bostwick, C.A.
Insulin-like growth factor-binding protein-5
induces pulmonary fibrosis and triggers
mononuclear cellular infiltration. Am. J. Pathol
; 169:1633-1642.
Sureshbabu A, Okajima H, Yamanaka D,
Shastri S, Tonner E, Rae C, Szymanowska M,
Shand JH, Takahashi S, Beattie J, Allan GJ, Flint
DJ. IGFBP-5 induces epithelial and fibroblast
responses consistent with the fibroticresponse.Biochem Soc Trans. 2009 Aug; 37(Pt
:882-5.
Sokolović A, Sokolović M, Boers W, Elferink
RP, Bosma PJ. Insulin-like growth factor binding
protein 5 enhances survival of LX2 human
hepatic stellate cells.Fibrogenesis Tissue Repair.
Feb 17; 3:3.
Sokolović A, Montenegro-Miranda PS, de
Waart DR, Cappai RM, Duijst S,Sokolović M,
Bosma PJ. Overexpression of insulin like growth
factor binding protein 5 reduces liver fibrosis in
chronic cholangiopathy. Biochim Biophys Acta.
Jun; 1822(6):996-1003.
Bach LA. IGFBP-6 five years on; not so
forgotten? Growth Horm.IGF res.15, 185-192.
Bach,L.A.,Fu,P.,Yang,Z. insulin like growth
factor binding protein-6 and cancer .Clin
.Sci.2013;124:215-229.
Romero, D.Endoglin regulates cancer-stromal
cell interactions in prostate tumors. Cancer
Res.2011; 71:3482-3493.
Kuo YS, Tang YB, Lu TY, Wu HC, Lin CT.
IGFBP-6 plays a role as an oncosuppressor gene
in NPC pathogenesis through regulating EGR-1
expression. J Pathol. 2010 Nov; 222(3):299-309.
Fu P, Thompson JA, Bach LA. Promotion of
cancer cell migration: anInsulin-like growth
factor (IGF)-independent action of IGF-binding
protein-6. J Biol Chem. 2007 Aug 3;
(31):22298-306.
Yang Y, Sheng M, Huang F, Bu D, Liu X, Yao
Y, Dai C, Sun B, Zhu J, Jiao Y, Wei Z, Zhu H, Lu
L, Zhao Y, Jiang C, Wang R. Downregulation of
Insulin-like growth factor binding protein 6 is
associated with ACTH-secreting pituitary
adenoma growth. Pituitary. 2014
Dec;17(6):505-13.
Raykha C, Crawford J, Gan BS, Fu P, Bach
LA, O'Gorman DB. IGF-II and IGFBP-6
regulate cellular contractility and proliferation in
Dupuytren's disease. Biochim Biophys Acta.
Oct;1832(10):1511-9.
Y.Oh, S.R.Nagalla, Y.Yamanaka.sythesis and
characterization of insulin like growth factor
binding protein (IGFBP)-7, J.Biol.Chem 1996.
Sato Y, Chen Z, Miyazaki K. Strong
suppression of tumor growth by insulinlike
growth factor-binding protein-related protein
/tumor-derived cell adhesion factor/mac25.
Cancer Sci 2007; 98:1055-63.
Wajapeyee N, Serra RW, Zhu X, Mahalingam
M, Green MR. Oncogenic BRAF induces
senescence and apoptosis through pathways
mediated by the secreted protein IGFBP7. Cell.
Feb 8;132(3):363-74.
Lin J, Lai M, Huang Q, Ruan W, Ma Y, Cui J.
Reactivation of IGFBP7 by DNA demethylation
inhibits human colon cancer cell growth in vitro.
Cancer Biol Ther. 2008 Dec; 7(12):1896-900.
Chen D, Yoo BK, Santhekadur PK, Gredler R,
Bhutia SK, Das SK, Fuller C, Su ZZ,Fisher PB,
Sarkar D. Insulin-like growth factor-binding
protein-7 functions as a potential tumor
suppressor in hepatocellular carcinoma. Clin
Cancer Res. 2011 Nov 1;17(21):6693-701.
Tomimaru Y, Eguchi H, Wada H, Kobayashi S,
Marubashi S, Tanemura M, Umeshita K, Kim T,
Wakasa K, Doki Y, Mori M, Nagano H. IGFBP7
downregulation is associated with tumor
progression and clinical outcome in
hepatocellular carcinoma. Int J Cancer. 2012 Jan
; 130(2):319-27.
Pollak M.Insulin-like growth factor signaling
in neoplasia.Nat Rev Cancer 2008; 8:915-928.
Zhang Y, Zhang QQ, Guo XH, Zhang HY, Liu
LX. IGFBPrP1 induces liver fibrosis by inducing
hepatic stellate cell activation and hepatocyte
apoptosis via Smad2/3 signaling. World J
Gastroenterol. 2014 Jun 7;20(21):6523-33.
Liu LX, Huang S, Zhang QQ, Liu Y, Zhang
DM, Guo XH, Han DW. Insulin-like growth
factor binding protein-7 induces activation and
transdifferentiation of hepatic stellate cells in
vitro. World J Gastroenterol. 2009 Jul 14;
(26):3246-53.
Guo XH, Liu LX, Zhang HY, Zhang QQ, Li Y,
Tian XX, Qiu ZH. Insulin-like growth factor
binding protein-related protein 1 contributes to
hepatic fibrogenesis. J Dig Dis. 2014
Apr;15(4):202-10.
Liu LX, Zhang HY, Zhang QQ, Guo XH.
Effects of insulin-like growth factor binding
protein-related protein 1 in mice with hepatic
All Content should be original and unpublished.
